SCHEMBL5151820

SCHEMBL5151820

COC(=O)c1ccc(OC(F)(C(=O)Cc2ccc(NC(=O)Nc3ccccc3F)c(C)c2)N2CCCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.48
MAPT P10636 4/20 0.46
NPC1 O15118 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 3/20 0.46
HTT P42858 2/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
ITGA4 P13612 5/20 0.41
LMNA P02545 2/20 0.39
AVPR2 P30518 1/20 0.38
PKM P14618 1/20 0.38
P2RY1 P47900 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CCR3 P51677 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5153663 0.93 ITGA4 (0.48) RAB9AMAPTHTTITGA4LMNA
SCHEMBL5150125 0.92 ITGA4 (0.44) RAB9AMAPTNPC1ITGA4LMNA
SCHEMBL5152799 0.91 ITGA4 (0.43) RAB9AMAPTNPC1SMN1; SMN2ITGA4
SCHEMBL5153046 0.91 MAPT (0.45) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL5151939 0.88 ITGA4 (0.50) RAB9AMAPTNPC1ITGA4MEN1
SCHEMBL5149635 0.86 MAPT (0.56) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL5153516 0.85 ITGA4 (0.48) RAB9AMAPTNPC1SMN1; SMN2KDM4E
SCHEMBL6210735 0.85 ITGA4 (0.50) RAB9AMAPTNPC1ITGA4LMNA
SCHEMBL5152020 0.85 ITGA4 (0.52) MAPTITGA4LMNAMEN1KMT2A
SCHEMBL5155453 0.84 ITGA4 (0.48) ITGA4P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 RAB9A 2225/4885MAPT 3414/4885NPC1 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.